Castle Biosciences (CSTL) Depreciation & Amortization (CF) (2018 - 2026)

Castle Biosciences has disclosed Depreciation & Amortization (CF) across 9 years of filings, most recently posting $3.9 million for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $3.9 million, down 86.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.9 million (down 64.79% YoY), and the FY2025 annual result was $40.8 million, up 154.87% from the prior year.
• Depreciation & Amortization (CF) came in at $3.9 million for Q1 2026 at Castle Biosciences, up from $3.8 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $29.8 million in Q1 2025 to a low of $2.2 million in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $3.3 million (2024), against an average of $4.9 million.
• Across the five-year window, Depreciation & Amortization (CF) soared 823.18% in 2022 and sank 86.8% in 2026, its largest moves.
• Castle Biosciences' Depreciation & Amortization (CF) stood at $2.8 million in 2022, then gained by 13.48% to $3.2 million in 2023, then surged by 78.91% to $5.8 million in 2024, then plunged by 34.52% to $3.8 million in 2025, then gained by 4.02% to $3.9 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $3.9 million (Q1 2026), $3.8 million (Q4 2025), and $3.8 million (Q3 2025), per Business Quant data.